Organization · Venture Capital
Tellus BioVentures
Tellus BioVentures is a U.S.-based biotechnology investment fund focused on early-stage innovation and company formation in life sciences. The firm invests in private biotech ventures at the Seed stage and participates in Series A investments.
Overview
What Tellus BioVentures does
What Tellus BioVentures is
Tellus BioVentures is a U.S.-based biotechnology investment fund focused on early-stage innovation and company formation in life sciences. The firm invests in private biotech ventures at the Seed stage and participates in Series A investments.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2019
- Approximate age
- About 7 years
- Structured capabilities
- Funder
- Last reviewed
- April 26, 2026
Official channels
Find Tellus BioVentures elsewhere
Open the official website or a supported primary organization account.
Capability profile
Tellus BioVentures as a funder
Investment thesis
Tellus BioVentures seeks promising life-science assets that require capital, focus, and operational support to develop into therapies. The firm aims to surround these assets with the right team and resources to accelerate their progress.
Focus narrative
Tellus BioVentures invests primarily in private biotech ventures at the Seed stage, often as the lead or sole investor, and also participates in Series A investments. The organization is committed to launching and funding de novo companies that advance significant innovations lacking necessary resources for efficient progress.
Value beyond capital
Tellus BioVentures provides management support and development expertise to its portfolio companies, helping them achieve critical milestones. The firm identifies value-inflection points and operates hands-on to transform innovative science into viable therapies for patients.
Focus and fit
- Stages
- Seed · Series A · Friends and Family
- Sectors
- Biotech & Life Sciences
- Regions
- United States
Availability
- Currently deploying
- Not published
Portfolio and track record
Portfolio context
Aegle Therapeutics: Developing extracellular vesicle therapy for rare diseases, including dystrophic epidermolysis bullosa. Dianthus Therapeutics: Creating monoclonal antibody therapeutics for autoimmune diseases. Interius BioTherapeutics: Innovating in vivo cell-specific gene delivery. Navrogen: Advancing antibody-drug conjugate therapeutics targeting tumor-produced factors. Praeventix: Developing therapies for serotonergic-driven disorders, including a clinical-stage anti-IGF-1R monoclonal antibody for thyroid eye disease. viTToria Biotherapeutics: Delivering next-generation T-cell therapies for unmet medical needs.
Common questions
What to know about Tellus BioVentures
Upseed classifies Tellus BioVentures under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 26, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.